基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 原料药 神经系统用药 阿杜那单抗 BART, BIIB-037, BIIB037, aducanumab-avwa
  • (Aducanumab)Biosimilar Reference Antibody-GS40014
  • (Aducanumab)Biosimilar Reference Antibody-GS40014

1/2

(Aducanumab)Biosimilar Reference Antibody-GS40014

Aducanumab
300 100μg 起订
湖北 更新日期:2026-03-16

武汉迈思生物科技有限公司

VIP1年
联系人:市场
电话:027-65523427拨打
手机:18007167883 拨打
邮箱:Service@mabnus.com

产品详情:

中文名称:
BART, BIIB-037, BIIB037, aducanumab-avwa
英文名称:
Aducanumab
CAS号:
1384260-65-4
品牌:
Mabnus
产地:
武汉
保存条件:
store at -20°C or -80°C. Avoid repeated freeze.
纯度规格:
>95% by SDS-PAGE
重组:
应用:
ELISA;FC;Functional Assays;IF
种属反应性:
Human
宿主:
Genetically human
偶联物:
靶点:
APP
免疫原:
APP
亚型:
IgG1 - kappa
验证方法:
(Aducanumab)Biosimilar Reference Antibody(GS40014) on SDS-PAGE under non-reducing (NR) and reducing (R) condition.

货号:GS40014

Aducanumab is a recombinant, fully human IgG1 monoclonal antibody developed for the treatment of Alzheimer's disease. It selectively targets aggregated forms of amyloid-beta (Aβ), specifically soluble oligomers and insoluble fibrils that constitute amyloid plaques in the brain. Its proposed mechanism is to bind to these pathogenic aggregates, promoting their clearance by microglia through Fc receptor-mediated phagocytosis, thereby reducing amyloid plaque burden. Approved by the U.S. FDA in 2021 under the accelerated approval pathway, it represents the first therapy to claim to address a core pathological process of Alzheimer's, though its clinical benefits and approval remain subjects of significant scientific and medical debate.



Aducanumab;

公司简介

武汉迈思生物科技有限公司立足于解决行业内功能活性蛋白表达及高亲和力、高灵敏度抗体开发难的痛点,依托自建的两大核心技术平台:哺乳动物细胞蛋白表达平台和单个B细胞抗体开发平台,竭诚为广大科研机构、高等院校、IVD企业、医药企业等提供一站式蛋白表达及抗体开发相关产品和技术服务。

成立日期 (5年)
注册资本 壹佰伍拾万圆人民币
员工人数 10-50人
年营业额 ¥ 1000万-5000万
经营模式 工厂,试剂,定制,服务
主营行业 抗体,蛋白组学

BART, BIIB-037, BIIB037, aducanumab-avwa相关厂家报价

内容声明
拨打电话 立即询价